CCR3 and neoplasm: A variety of chemokine/chemokine receptor strategies have been utilised in immunotherapeutic T cell preclinical work to facilitate CAR T cell targeting to tumour masses, including the exploiting the CXCR3, CXCR2, CCR5, CCR2, and CCR3 axes.